Contact
QR code for the current URL

Story Box-ID: 1156658

EvidentIQ Group GmbH Rathausmarkt 5 20095 Hamburg, Germany https://evidentiq.com
Contact Mr David Renzelmann 089452277500

E2B Mailer: Safety Notifications Made Easy

Monitor adverse drug reactions (ADRs) outside of the scope of a full PV system

(PresseBox) (Hamburg, )
EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system.  

EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse drug reactions (ADRs) outside of the scope of a full PV system in a trial or non-interventional study. After much research and engineering time they came up with the E2B Mailer.  

The E2B Mailer is a new safety notification solution that provides an auto forward functionality of (Serious) Adverse Events in E2B and archivable format. It has the great advantage of being EDC agnostic, so it can adapt to any study and/or software.  

It has been proven to perfectly bridge the gap between a full PV and a simple reposting system. The E2B mailer is tailored to provide a streamlined way to monitor ADRs. It uses automated algorithms to detect potential ADRs and sends notificationwww.evidentiq.coms to investigators in real-time. This ensures that potential safety issues are identified and reported promptly, reducing the risk of harm to patients. By being EDC agnostic, the safety notification tool ensures that the user can focus on conducting its NIS without having to worry about the compatibility of the ADR monitoring and reporting system. 

EvidentIQ offers highly robust, reliable, and secure applications that scale elastically and cost-effectively. The E2B mailer offers high reliability (99.05%), PDFs highlighting changes, encryption at rest and in transit, E2B attachments to connect to PV Systems, and it also includes special use cases for non-interventional studies.

EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, the UK, Italy, Canada, Japan and China.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.